ClinicalTrials.gg
RecruitingNCT06880055SOLARUpdated Nov 12, 2026

Shield Post-Approval Study Protocol

An observational study in Colo-rectal Cancer, sponsored by Guardant Health, Inc.. Recruiting at 83 sites in United States. Open to participants aged 45 Years to 81 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Guardant Health, Inc. · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 12, 202614 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,375
Ages
45 Years to 81 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,123 studies in Colonic Neoplasms with a site in United States — 115 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.

Planned enrollment
19th of 181
3,375 · median 220
Started
2025
with 32 others
Observational
181 of 1,123
30 open now
Primary completion
2030-09
later than 174 of 187 live
Registered
1,070th of 1,123
by date

Among the 1,123 studies in Colonic Neoplasms with a site in United States, this one is the 19th largest by planned enrollment of the 181 observational ones that give a count, is one of 33 that started in 2025, is one of 181 observational ones, reaches primary completion later than 174 of the 187 other live ones, and was the 1,070th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

115 of the 1,123 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 45 Years to 81 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,123 studies in Colonic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC using colonoscopy as the reference method.

Read the detailed description

Colorectal cancer (CRC) is the fourth most diagnosed cancer and second leading cause of cancer-related death in the US, with an estimated 53,010 deaths attributable to CRC in 2024. The risk of CRC increases with age, with the majority of cases and deaths occurring in individuals aged 65 years or older. While the incidence of CRC in Americans 65 years of age or older has decreased over the last decade, the incidence of CRC in younger Americans aged 55 years or younger has been increasing since the mid-1990s. CRC disproportionately affects minority populations, with American Indian/Alaska Native and Black/African American populations having the highest incidence and mortality rates1; this is further exacerbated by systemic barriers to current CRC screening options.

CRC primarily arises from a precursor lesion, the adenomatous polyp (i.e., adenoma), that grows from the epithelial cells of the colorectal mucosa. Adenomas that grow larger than 10 mm or have elements indicating a risk of malignant transformation (e.g., high-grade dysplasia or villous features) are defined as advanced adenomas (AAs). The vast number of adenomas, even those with features classifying them as AAs, do not progress into a colorectal malignancy. Colonoscopy cannot always distinguish adenomas or advanced adenomas from other polyp histology; thus, polypectomy is routinely performed for lesions identified on endoscopy. The transition rate from adenoma onset to CRC development is estimated to be 12.5 to 25 years. This slow transition from adenoma onset to CRC onset allows for multiple CRC screening opportunities over a lifetime, providing the ability to intervene along the disease development course and the potential to detect and remove adenomas, prevent colorectal cancer, and reduce CRC incidence and subsequently, disease mortality.

Once CRC has developed, tumor staging is consistent with other solid tumors and defined based on how far the cancer has spread within the body. In Stage 0 (carcinoma in situ), the cancer cells are only in the colorectal mucosa. In Stage I, the cancer has spread to the muscular layer of the colorectum but not to nearby tissue or lymph nodes. In Stage II, the cancer has grown through the wall of the colorectum and potentially to nearby tissues but has not spread to nearby lymph nodes. In Stage III, the cancer has spread to nearby lymph nodes but not to distant parts of the body. In Stage IV, the cancer has spread to one or more distant parts of the body. The estimated time frame from CRC onset to a symptomatic diagnosis of CRC is estimated to be 4-5 years, in the absence of early detection through asymptomatic cancer screening. Tumor size and location can influence the rate of transition through the stages of CRC. The 5-year survival rate for localized disease (Stage I-II) is 91%, and is 72% for regional disease (Stage III), while the 5-year survival for metastatic disease (Stage IV) is only 14%. These statistics highlight the ability to reduce CRC-related mortality by detection of early-stage (Stage I-III) disease where therapeutic intervention has the potential to result in a cure.

03

Conditions studied

  • Colo-rectal Cancer

Browse trials for

Keywords

  • Screening
  • Shield
04

Who can participate

Ages eligible
45 Years to 81 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Subjects age 45 to 81 at average risk of CRC who meet inclusion, do not meet exclusion criteria, and who successfully enroll in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 45-81 years at time of consent
  2. Intending to undergo a standard of care Shield test
  3. Considered by a physician or healthcare provider as being of 'average risk' for CRC; 'Average-risk' individuals in the context of CRC screening are defined as those who do not have symptoms of CRC and do not have increased risk factors for the disease (i.e., prior diagnosis of CRC, adenomatous polyps, or inflammatory bowel disease; family history of CRC or known hereditary predisposition to CRC).
  4. Subject agrees to comply with study procedures and associated standard of care assessments.

Exclusion criteria

Exclusion Criteria:

  1. Undergoing colonoscopy for investigation of symptoms
  2. Personal history of colorectal cancer (CRC), adenomas, or other related cancers
  3. Family history of CRC, defined as having one or more first-degree relative (parent, sibling, or child) diagnosed with CRC at any age
  4. Positive result on another colorectal cancer screening method within the last six months, or:

    • 12 months for fecal occult blood test (FOBT) or fecal immunochemical test (FIT)
    • 36 months for FIT-DNA test
  5. Personal history of any of the following high-risk conditions for colorectal cancer:

    • Inflammatory Bowel Disease (IBD), including chronic ulcerative colitis (CUC) and Crohn's disease
    • Familial adenomatous polyposis (FAP)
    • Other hereditary cancer syndromes including but not limited to:

      • Hereditary non-polyposis colorectal cancer syndrome (HNPCC) or "Lynch Syndrome", Peutz- Jeghers Syndrome, MUTYH Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis
  6. Positive Shield test result within the previous 3 years
  7. History of any (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of for the study)
  8. Known diagnosis of inflammatory bowel disease
  9. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs (DMARDs)
  10. Any major physical trauma (e.g., disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent
  11. Known medical condition which, in the opinion of the Investigator, should preclude enrollment into the study
  12. Participation in a clinical research study in which an experimental medication has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of colonoscopy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,375 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Enrolled Subjects

    Subjects age 45 to 81 at average risk of CRC who meet inclusion, do not meet exclusion criteria, and who successfully enroll in the study.

    Diagnostic Test: Shield Blood Test for colo-rectal cancer Screening

Interventions

  • Diagnostic testShield Blood Test for colo-rectal cancer Screening

    Shield Blood Test for colo-rectal cancer Screening

06

What researchers measure

Primary outcomes

  1. Performance measures of the Shield test will be assessed for the second testing interval

    * Advanced Neoplasia Specificity * AA Sensitivity * CRC Sensitivity * PPV for: CRC, AA, and advanced neoplasia. * NPV for: CRC and advanced neoplasia

    Time frame: 33-42 Months Post-Enrollment

07

Study locations

72 of 83 sites recruiting
  • Southeast Valley Gastroenterology Consultants
    Chandler, Arizona 85224, United States
    Recruiting
    • Charles Schron · Contactcmsphoenix@aol.com · 480-899-2994
    • Charles Schron · Principal investigator
  • Southeast Valley Gastroenterology Consultants
    Gilbert, Arizona 85297, United States
    Recruiting
    • Charles Schron · Contactcmsphoenix@aol.com · 480-899-2994
    • Charles Schron · Principal investigator
  • Elite Primary Physicians, Inc.
    Anaheim, California 92805, United States
    Recruiting
  • Alliance Research Institute, LLC
    Canoga Park, California 91304, United States
    Recruiting
  • Paragon Rx Clinical, Inc.
    Garden Grove, California 92840, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Amicis Research Center
    Granada Hills, California 91344, United States
    Recruiting
  • Ace Research Institute
    Monterey Park, California 91754, United States
    Recruiting
  • Desert Oasis Healthcare Medical Group
    Palm Springs, California 92262, United States
    Recruiting
    • Brooke Yates · Contactbyates@mydohc.com · 760-320-9505
    • Michael F Jardula · Principal investigator
  • Amicis Research Center
    Sherman Oaks, California 91403, United States
    Recruiting
  • BioPartners, Inc
    Tarzana, California 91356, United States
    Recruiting
    • Mila Gor · Contact818-712-9355
    • Arkady Stern, MD · Principal investigator
  • Amicis Research Center
    Valencia, California 91355, United States
    Recruiting
  • Coral Clinics
    Winnetka, California 91306, United States
    Recruiting
  • BioPartners, Inc
    Woodland Hills, California 91367, United States
    Recruiting
  • Digestive Disease Associates
    Branford, Connecticut 06405, United States
    Recruiting
    • Lillian Urrutia · ContactLurrutia@yanuvia.com · 561-453-3215
    • Daniel Zanchetti · Principal investigator
  • Digestive Disease Associates
    Branford, Connecticut 06405, United States
    Recruiting
    • Alan Bernegger · Contactabernegger@yanuvia.com · 920-472-1093
    • Daniel Zanchetti, MD · Principal investigator
  • Gastroenterology Consultants of Boca Raton, LLC
    Boca Raton, Florida 33486, United States
    Recruiting
    • Lillian Urrutia · ContactLurrutia@yanuvia.com · 561-453-3215
    • Todd Eisner · Principal investigator
  • Manuel Espinel MD PA
    Delray Beach, Florida 33484, United States
    Recruiting
  • Innova Pharma Research, LLC
    Doral, Florida 33172, United States
    Recruiting
  • Marisela Gonzalez, MD
    Miami, Florida 33134, United States
    Recruiting
  • Research Associates of South Florida, LLC
    Miami, Florida 33134, United States
    Recruiting
  • Florida South Research Phase I-IV, Inc.
    Miami, Florida 33166, United States
    Recruiting
  • Physicians Group of South Florida
    North Miami, Florida 33181, United States
    Recruiting
  • Infinity Life Research Group, LLC
    Tamarac, Florida 33321, United States
    Recruiting
  • NMC Research
    Tampa, Florida 33607, United States
    Recruiting
  • Top Research of West Florida, LLC
    Tampa, Florida 33634, United States
    Recruiting
    • Mabel Diaz · Contactmdiaz@topresearch.org · 813-290-0648
    • Jorge Castillo Molina, MD · Principal investigator
  • Keith Family Medicine
    Conyers, Georgia 30094, United States
    Recruiting
  • Keith Family Medicine
    Dawsonville, Georgia 30534, United States
    Recruiting
  • Primeway Clinical Research Group
    Fayetteville, Georgia 30214, United States
    Recruiting
  • CLINsearch at Renew Health Clinical Research
    Snellville, Georgia 30078, United States
    Recruiting
  • Digestive Disease Consultants
    Bourbonnais, Illinois 60914, United States
    Recruiting
  • Digestive Disease Consultants
    Bourbonnais, Illinois 60914, United States
    Recruiting
  • Christie Clinic
    Champaign, Illinois 61822, United States
    Recruiting
  • Christie Clinic
    Champaign, Illinois 61822, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • GI Solutions of Illinois
    Chicago, Illinois 60631, United States
    Recruiting
  • GI Solutions of Illinois
    Chicago, Illinois 60631, United States
    Recruiting
  • Digestive Health Services
    Downers Grove, Illinois 60515, United States
    Recruiting
  • Digestive Health Services
    Downers Grove, Illinois 60515, United States
    Recruiting
  • Gastroenterology and Internal Medicine Specialists (GAIMS)
    Lake Barrington, Illinois 60010, United States
    Recruiting
  • Gastroenterology and Internal Medicine Specialists (GAIMS)
    Lake Barrington, Illinois 60010, United States
    Recruiting
  • Northshore Center for Gastroenterology (NCG)
    Libertyville, Illinois 60048, United States
    Recruiting
  • Southwest Gastroenterology (SWG)
    Oak Lawn, Illinois 60453, United States
    Recruiting
  • Southwest Gastroenterology (SWG)
    Oak Lawn, Illinois 60453, United States
    Recruiting
    • Hussain Boxwalla Chief Operating Officer/Owner · Contacthboxwalla@avicennaclinical.com · (708) 860-7866
    • Charles Berkelhammer, MD · Principal investigator
  • Center for Digestive Health
    Munster, Indiana 46321, United States
    Recruiting
  • Hutchinson Clinic
    Hutchinson, Kansas 67502, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northlake Gastroenterology Associates
    Covington, Louisiana 70433, United States
    Recruiting
  • Northlake Gastroenterology Associates
    Hammond, Louisiana 70403, United States
    Recruiting
  • Olney Medical Group
    Olney, Maryland 20832, United States
    Recruiting
  • Embassy Research Network
    Bloomfield Township, Michigan 48302, United States
    Recruiting
  • Tanir Medical Center, PC
    Clarkston, Michigan 48346, United States
    Recruiting
  • Quinn Healthcare, PLLC
    Ridgeland, Mississippi 39157, United States
    Recruiting
  • Gastroenterology Associates of New Jersey, LLC
    Clifton, New Jersey 07013, United States
    Recruiting
  • Gastroenterology Associates of New Jersey
    Hackensack, New Jersey 07601, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Gastroenterology Associates of New Jersey, LLC
    Montclair, New Jersey 07042, United States
    Recruiting
  • Gastroenterology Associates of New Jersey, LLC
    Ridgewood, New Jersey 07450, United States
    Recruiting
  • Gastroenterology Associates of New Jersey, LLC
    Wayne, New Jersey 07470, United States
    Recruiting
  • Gastroenterology Associates of New Jersey
    Wayne, New Jersey 07470, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Associated Gastroenterologists of Central New York
    Camillus, New York 13031, United States
    Recruiting
  • Syracuse Gastroenterological Associates, P.C.
    East Syracuse, New York 13057, United States
    Recruiting
  • Associated Gastroenterologists of Central New York
    Fayetteville, New York 13066, United States
    Recruiting
  • NYU Langone
    New York, New York 10010, United States
    Recruiting
  • Orchard Park Family Practice
    Orchard Park, New York 14127, United States
    Recruiting
  • GastroCare LI
    Valley Stream, New York 11581, United States
    Recruiting
  • GastroCare LI
    Valley Stream, New York 11581, United States
    Recruiting
    • Alan Bernegger · Contactabernegger@yanuvia.com · 920-472-1093
    • Brandon Rieders, MD · Principal investigator
  • Cary Gastroenterology Associates
    Cary, North Carolina 27518, United States
    Recruiting
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
    Recruiting
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
    Recruiting
  • University of North Carolina at Chapel Hill
    Hillsborough, North Carolina 27278, United States
    Recruiting
  • Piedmont Healthcare, P.A.
    Mocksville, North Carolina 27028, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Pinehurst Medical Clinic
    Pinehurst, North Carolina 28374, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Sanford Cardiology Pinehurst Medical Clinic
    Sanford, North Carolina 27330, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Piedmont Healthcare LLC
    Statesville, North Carolina 28625, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • US Digestive Health at Blair
    Altoona, Pennsylvania 16602, United States
    Recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Health Living at Pottstown Medical Specialists, Inc
    Pottstown, Pennsylvania 19464, United States
    Recruiting
  • Premier Family Physicians
    Austin, Texas 78735, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Premier Family Physicians
    Austin, Texas 78746, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Broadway Medical Clinic
    Garland, Texas 75043, United States
    Recruiting
  • Integrity Advanced Therapeutics, PLLC
    Houston, Texas 77090, United States
    Recruiting
    • Scott Ward · Contactscott.ward@iat.care · 281-453-2005
    • Howard Hamat · Principal investigator
  • Paris Family Physicians
    Paris, Texas 75460, United States
    Recruiting
  • Center for Digestive Disease
    Shenandoah, Texas 77384, United States
    Recruiting
  • Horizon Clinical Research Group
    Tomball, Texas 77375, United States
    Recruiting
  • Horizon Clinical Research Group
    Tomball, Texas 77375, United States
    Recruiting
  • Tidewater Physician Multispecialty Group Clinical Research
    Williamsburg, Virginia 23188, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Sep 2030, 61 months after the start.

Of 225 observational studies under Colonic Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 116. This study's planned 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 17, 2025
StartActual
Jul 14, 2025
Primary completionEst.
Sep 1, 2030
CompletionEst.
Dec 1, 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites added
Show 14 added (14 United States)
  • Ace Research Institute · Monterey Park, United States
  • BioPartners, Inc · Tarzana, United States
  • BioPartners, Inc · Woodland Hills, United States
  • Infinity Life Research Group, LLC · Tamarac, United States
  • Top Research of West Florida, LLC · Tampa, United States
  • Keith Family Medicine · Conyers, United States
  • Keith Family Medicine · Dawsonville, United States
  • Primeway Clinical Research Group · Fayetteville, United States
  • CLINsearch at Renew Health Clinical Research · Snellville, United States
  • Center for Digestive Health · Munster, United States
  • Olney Medical Group · Olney, United States
  • Tanir Medical Center, PC · Clarkston, United States
  • Broadway Medical Clinic · Garland, United States
  • Paris Family Physicians · Paris, United States
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    14 sites added
    Show 14 added (14 United States)
    • Ace Research Institute · Monterey Park, United States
    • BioPartners, Inc · Tarzana, United States
    • BioPartners, Inc · Woodland Hills, United States
    • Infinity Life Research Group, LLC · Tamarac, United States
    • Top Research of West Florida, LLC · Tampa, United States
    • Keith Family Medicine · Conyers, United States
    • Keith Family Medicine · Dawsonville, United States
    • Primeway Clinical Research Group · Fayetteville, United States
    • CLINsearch at Renew Health Clinical Research · Snellville, United States
    • Center for Digestive Health · Munster, United States
    • Olney Medical Group · Olney, United States
    • Tanir Medical Center, PC · Clarkston, United States
    • Broadway Medical Clinic · Garland, United States
    • Paris Family Physicians · Paris, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06880055
Lead sponsor
Guardant Health, Inc.
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Jul 14, 2025
Primary completion
Sep 1, 2030 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Hannah Oakley
Contact
solar@guardanthealth.com
415-307-2774

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion